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Abstract. Keratin 5 (K5) is present in the basal layer of a 
stratified squamous keratinized and non‑keratinized epithe‑
lium. K5 and K14 have been demonstrated in the mucosa 
and tumors of the oral cavity, oropharynx, hypopharynx and 
larynx, and in the mitotic active basal cells of a stratified 
squamous epithelium. The aim of the present study was to 
assess K5 expression in squamocellular carcinoma with 
various localizations in the head and neck. A total of 13 biopsy 
fragments were included from patients diagnosed with 
squamocellular carcinoma of the larynx area (n=2), pharynx 
(n=2), hard palate (n=1), tongue (n=2), submandibular (n=1), 
lip (n=1), gingival sulcus (n=1), nasal pyramid (n=1), maxilla 
(n=1) and zygomatic (n=1). The immunohistochemical 
staining for K5 was evaluated according to the following 
score criteria: 0 (0% positive cells); 1 (<10% positive cells); 
2 (10‑30% positive cells); and 3 (>30% positive cells). K5 
expression was observed in all squamocellular carcinomas 
included in the present study with scores between 1 and 3. For 
well‑ and moderately‑differentiated histopathological types, 
a maximum score of 3 was recorded for all of the cases, not 
including the laryngeal area, which presented a score of 2. 
The following scores were identified in the regions of the 
poorly differentiated carcinomas: Jaw, 3; gingival sulcus, 2; 
and tongue and submandibular area, 1. These observations 
may aid with an improved stratification of head and neck 
squamocellular carcinoma, thus improving the diagnosis and 
treatment strategies for this type of cancer.
Introduction
Cytokeratins (CKs) are proteins of the intermediary fila‑
ments of keratin, situated intracytoplasmically and present 
in the cytoskeleton of all epithelial cells. The term CK was 
initially used at the end of the 1970s (1) when the protein 
subunits of the intermediary filaments from the inside of 
cells were identified and characterized for the first time. A 
novel nomenclature for keratins was established in 2006, 
and the proteins that were previously known as CKs were 
termed keratins (Ks) (2). There are two types of Ks: Acidic 
(type I) and basic (type II). K5 is present at the level of the 
basal layer of the keratinized and non‑keratinized stratified 
squamous epithelia. K5 expression is decreased at the level 
of the spinosum stratum of the normal oral mucosa, and in 
the dysplastic epithelium, K5 is positive in the basal, para‑
basal and stratum spinosum cells. In the case of cancers, 
Ks serve predominantly as tumor markers for diagnostic 
procedures. Therefore, in the case of breast cancer, an asso‑
ciation between the young age of patients at presentation and 
the basal‑like subtype (characterized by the absence of the 
expression of estrogen, progesterone and human epidermal 
growth factor receptor 2 receptors, and the presence of 
epidermal growth factor receptor and K5 and K6 expression) 
has been recorded. Additionally, a higher tumor grade has 
been associated with a prognosis of approximately five years 
of disease‑free‑survival (3,4).
Squamocellular carcinomas, independently from their 
origin, are characterized by the expression of the Ks of the 
stratified epithelia (K5, K14 and K17) and overexpression of 
K6 and K16 in hyperproliferating strata (5). The combined 
overexpression of K5 and K14 was demonstrated in tumors 
of the oral cavity, in the oropharyngeal, hypopharyngeal and 
laryngeal areas (6,7) and in the basal actively mitotic cells 
of the squamous stratified epithelium (8). The expression 
of K5 and K14 remains high even if the malignant grading 
decreases (9‑11).
Using these data as a stratification method, the aim of 
the present study was to identify the K5 expression features 
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in the squamocellular carcinoma that were located in various 
regions of the oral and maxillofacial area in order to improve 
the diagnostic accuracy.
Materials and methods
Patients and specimens of squamocellular carcinoma. A total 
of 13 biopsy fragments were evaluated, which were obtained 
from patients that had been diagnosed with squamocellular 
carcinoma in the following areas; larynx (n=2), pharynx (n=2), 
hard palate (n=1), tongue (n=2), submandibular (n=1), lip (n=1), 
gingival sulcus (n=1), nasal pyramid (n=1), maxilla (n=1) and 
zygomatic (n=1). Patients provided written informed consent. 
Immunohistochemistry analysis. The biopsy fragments were 
placed into buffered formalin (10%) for 48 h and subsequently 
paraffin was added. All stages of the immunohistochemical 
technique were facilitated by the use of an automated 
immunohistochemistry instrument (Leica Bond‑III; Leica 
Microsystems, GmbH, Wetzlar, Germany), according to the 
manufacturer's instructions and using a primary monoclonal 
mouse antibody specific for CK5 (clone XM26, ready to use; 
Novocastra Laboratories Ltd., Newcastle upon Tyne, UK). 
Following dehydration in pure alcohol, the sections were placed 
in benzene to replace ethanol prior to embedding in paraffin 
and subsequently fitted using Canada balsam (Sigma‑Aldrich, 
St. Louis, MO, USA). The microscopic evaluation was 
performed with a Nikon Eclipse E600 microscope (Nikon 
Corporation, Tokyo, Japan) and the images were obtained using 
the Laboratory Universal Computer Image Analysis G system 
(Laboratory Imaging Co., Prague, Czech Republic). The 
immunohistochemistry for K5 in the tumor cells was evalu‑
ated according to the following scores: 0 (0% CK5‑positive 
cells), 1 (<10% CK5‑positive cells), 2 (10‑30% CK5‑positive 
cells) and 3 (>30% CK5‑positive cells).
Results
Score of CK5 expression in  various squamocellular carci-
noma. The morphological labeling indicated the presence of 
seven cases of well‑differentiated squamocellular carcinoma 
(two larynx, two pharynx, one nasal pyramid, one lip and 
one zygomatic), two were moderately differentiated (tongue 
and hard palate) and four were poorly differentiated (tongue, 
submandibular area, maxillary and gingival sulcus). In certain 
cases, at the level of the larynx, scores of 2 were observed in 
addition to the presence of two distribution models, which were 
as follows: i) Homogeneous distribution, all the cells in the 
tumor area were positive for CK5 labeling; and ii) heteroge‑
neous distribution, the CK5‑positive cells were prevalent at the 
periphery of the tumor areas. However, the distribution of the 
immunohistochemical staining score was always 2 (Fig. 1A).
For the second case that originated from the larynx, the 
score was 3, the distribution was homogeneous and a prevalent 
cytoplasmic pattern was demonstrated (Fig. 1B).
The well‑differentiated squamocellular carcinoma cases, 
originating from the pharynx, exhibited a CK5 expression 
score of 3 with a homogeneous distribution pattern and 
Figure 2. Squamocellular carcinoma. Immunohistochemical staining for cytokeratin 5 in the (A) lip (score, 3); magnification, x40; (B) nasal pyramid (score, 3); 
magnification, x40; and (C) zygomatic (score, 3); magnification, x20.
Figure 1. Squamocellular carcinoma. Immunohistochemical staining for cytokeratin 5 in the (A) larynx (score, 2); magnification, x10; (B) larynx (score 3); 
magnification, x40; and (C) pharynx (score, 3); magnification, x20.
  A   B   C
clone XM26; RTU, 
  A   B   C
ONCOLOGY LETTERS 3
intense immunohistochemical staining (Fig. 1C). All of the 
squamocellular carcinoma cases originating from the lip, 
nasal pyramid and zygomatic area had a well‑differentiated 
grade. These cases were all highly positive for CK5 expres‑
sion (score, 3) with either a cytoplasmic or mixed (cytoplasmic 
and membrane) pattern and a homogeneous distribution 
(Fig. 2A‑C).
Moderately‑differentiated squamocellular carcinoma 
cases originating from the lip and hard palate demonstrated a 
homogeneous distribution of CK5 in all the cells of the tumor 
area with a score of 3.
Intensity and expression pattern of CK5. With regard to 
the intensity of the immunohistochemical staining and the 
associated expression pattern, the following were observed: 
i) Maximal intensity and a cytoplasmic pattern in the isolated 
cells, in addition to a mixed pattern in the carcinomas located 
in the lip (Fig. 3A). ii) Heterogeneity of the intensity of the 
immunohistochemical staining (moderate and intense), 
however, with an expression pattern that was comparable 
between those that originated from the lip and the carcinomas 
that originated from the hard palate (Fig. 3B).
For all the four cases that were included in the 
poorly‑differentiated grade carcinoma category located 
in the tongue, submandibular area, maxillary and gingival 
sulcus, a marked reduction in the scores for the CK5 
immunohistochemistry was observed; for squamocellular 
carcinoma originating from the tongue, a score of 1 was 
observed (Fig. 3C). The cells that were positive for CK5 
were dispersed among the cells that did not express CK5 
and exhibited a decreased reaction intensity and cytoplasmic 
expression pattern.
The squamocellular carcinoma case originating from the 
submandibular area presented isolated regions with posi‑
tive cells in the tumor area (score, 1) as well as cytoplasmic 
expression (Fig. 4A). For the case originating from the upper 
jaw area, a high score of 3 was observed (Fig. 4B).
The squamocellular carcinoma that originated from the 
gingival sulcus area preserved the same mixed aspect with 
positive and negative cells present at the level of the tumor 
areas. In this case, the intensity of the reaction was moderate 
Figure 3. Squamocellular carcinoma. Immunohistochemical staining for cytokeratin 5 in the (A) lip (score, 3); magnification, x40; (B) hard palate (score, 3); 
magnification, x40; and (C) tongue (score, 1); magnification, x10.
Figure 4. Squamocellular carcinoma. Immunohistochemical staining for cytokeratin 5 in the (A) submandibular (score, 1); magnification, x40; (B) upper jaw 
(score, 3); magnification, x40; and (C) gingival sulcus (score, 2); magnification, x40.
Figure 5. Ratio between the values of the score that indicates the percentage 
of the positive cytokeratin 5 tumoral cells and the various areas where the 
squamocellular carcinomas were located.
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(score, 2) and the expression patterns were cytoplasmic or 
mixed (Figs. 4C and 5).
Discussion
Expression of CK5 and CK14 was found to be specific for 
mucosal areas and for tumors that originated from the oral 
cavity, oropharynx, hypopharynx and larynx, and in the basal 
actively mitotic cells of the squamous stratified epithelia (8). 
Velluci et al (9) and Marley et al (10) observed a decreased 
expression of CK5 and CK14 along with malignant altera‑
tions; however, the expression did not cease completely. The 
presence of K5 expression was observed in all of the cases of 
squamocellular carcinoma that were included in the present 
study.
Kaufmann et al (12) demonstrated a high expression 
of CK5 and CK6 in 81% of squamocellular carcinomas 
that were included in their study, with an intense immu‑
noexpression, which was diffuse in the majority of the 
tumoral cells. In comparison to squamocellular carcinomas, 
Kaufmann et al observed that only 14.2% of the non‑squa‑
mocellular carcinomas expressed CK5 and CK6, with 
distribution in a reduced number of tumor cells. In the present 
study, all the cases of squamocellular carcinomas originating 
from the oral and maxillofacial areas expressed CK5 in the 
tumor cells, with scores ranging from 1 to 3. Whereas, the 
variation between the intensity scores for CK5/6 and p63 was 
relatively small in a previous study (12). Crook et al (13) high‑
lighted that p63 expression in squamocellular carcinomas is 
not dependent on the tumoral grade, as it was identified to 
be strongly expressed in all cases of poorly‑differentiated 
carcinoma originating from the nasopharynx. The same 
expression was recorded for CK5 and CK6. In the present 
study, a decrease of CK5 expression was observed in two 
of the poorly‑differentiated squamocellular carcinoma 
cases; one originating from the tongue and the other from 
the submandibular area, with scores of 1 (between 10‑30% 
of positive tumoral cells). An intermediate score of 2 was 
observed in the case originating from the gingival sulcus. 
Maintenance of the maximal score of 3 was observed in the 
case that originated from squamocellular carcinomas located 
in the upper jaw. Malzahn et al (14) and Tot (15) reported 
differences between p63, and CK5 and CK6 expression in 
breast carcinoma, where CK5 and CK6 were positive in 61% 
of the cases, compared with p63 that was expressed in 11% of 
the cases that were included in the study.
According to Chung et al (16) specific Ks, such as K14 
and K15, are associated the molecular classification of squa‑
mocellular carcinomas based on gene analysis, however, the 
expression of CK5 and CK6 have not been analyzed. The 
present study promotes the introduction of CK5 in classifying 
the subtypes of squamocellular carcinomas.
In conclusion, CK5 was expressed in all of the types of 
squamocellular carcinoma that were included in the present 
study, with scores varying from 1 to 3 and a higher expression 
observed in the poorly‑differentiated carcinomas as follows: 
A score of 3 for those originating from the jaw, 2 for the one 
originating from the gingival sulcus, and 1 for carcinomas 
of the tongue and submandibular area. The expression was 
present for well‑ and moderately‑differentiated histopatho‑
logical grades with a maximal score of 3 for all of the cases, 
with the exception of one carcinoma of the larynx where the 
score was 2. The present study confirms the role of CK5 in the 
definition of the differentiation of squamocellular carcinoma 
of head and neck revealing a differential expression depending 
on the anatomic site of the primary tumour. On these bases, 
additional studies on a larger series of patients are required.
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